The US FDA’s plan to have sponsors submit up to 10 proposed suffixes for a biological product’s distinguishable nonproprietary name should reduce the review burden on agency staff while also helping to ensure that a company gets one of its preferred suffixes approved instead of having the agency assign one.
In a final guidance released Jan. 12 on biological product nonproprietary naming, the agency requests sponsors of biologic...